Pfffttt....
Its just not that hard to figure it out.
Redman is gonna flush 10 years of work, research and $15,000,000+ in accredited investment and sacrifice a public company that should easily be maintaining a market cap of $100,000,000 for a $4M note?
Oh, and he is also gonna defer $1,150,000ish in compensation and restrict his own shares, as part of a self enrichment scheme? LOL…
That scenario wouldn’t fly as a bedtime story to a 6 year old child.
Redman has stated several times that he is looking for Asian investors. If he planned to dilute ONCX into a worthless company, why do the new investors need to be Asian?
They don’t. He can get more toxic financing anytime he wants.
The fact that he specifically mentions Asia indicates that he is looking to monetize the patents or distribution rights in both Japan and Korea where they own patents for Cancer treatment relating to Prolanta.
The successful completion of the second dosing group of phase one FDA trials could give them an opportunity to refinance the note with non-dilutive financing.
If phase one is a failure, Redman, Greenville Health, accredited investors and note holders lose everything along with shareholders.
Redman’s structuring of the company, the debt and compensation seem to indicate that he believes that phase one will do well.
Sorry for the long post. I am trying to keep them shorter.
LOL, IMO and FWIW.
News 
Market Data 
Discover 
AI
